Company: OPGN
Filing Date: 2025-08-21
Form Type: 10-K
Source: 0001829126-25-006628
Chunk: 2077

Company: OPGEN INC
Filing Date: 2025-08-21
Form: 10-K
Item: Item 12
Chunk 2077
---
 results of operations, financial position or cash flows.

    F-19

Note 4 – Revenue from Contracts with Customers

Disaggregated Revenue

The Company provided listing sponsorship and consulting services to growth-stage private companies, diagnostic test products and laboratory services to hospitals, clinical laboratories and other healthcare providing customers, and entered into collaboration agreements with government agencies, non-governmental organizations, and healthcare providers. The revenues by type of service consist of the following:

    Schedule of revenues by type of service

    Years Ended December 31,

    2024

    2023

    Product sales
     
    $
    169,373

    $
    2,400,053

    Laboratory services

    26,776

    153,719

    Listing sponsorship services

    5,000,000

    -

    Collaboration revenue

    -

    864,548

    Total revenue
     
    $
    5,196,149

    $
    3,418,320

Revenues by geography are as follows:

    Schedule of revenues by geography

    Years Ended December 31,

    2024

    2023

    Domestic
     
    $
    196,149

    $
    678,093

    International

    5,000,000

    2,740,227

    Total revenue
     
    $
    5,196,149

    $
    3,418,320

Deferred revenue

Changes in deferred revenue for the period were as follows:

    Schedule of changes in deferred revenue

    Balance at December 31, 2022
     
    $
    142,061

    Contracts with customers

    74,109

    Recognized in the current period

    (144,196
    )
  
    Currency translation adjustment

    (46,048
    )
  
    Balance at December 31, 2023

    25,926

    Recognized in the current period

    (21,096
    )
  
    Refunded to customers in the current period

    (4,830
    )
  
    Balance at December 31, 2024
     
    $
    -

    F-20

Note 5 – Investment in equity securities

On January 2, 2024, AEI Capital Ltd., the Company’s controlling stockholder (“AEI Capital”), entered into a Letter of Engagement with a privately held company